Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs Holdings (NASDAQ: ESTA) reported a record $30.3 million in sales for Q1 2021, up 24% from the previous year. The company raised its full-year revenue guidance to $118-$122 million, reflecting a 39% to 44% growth. First-quarter gross profit increased to $20.1 million (66.2% of revenue), while operating expenses decreased to $22.2 million. The net loss from operations improved to $2.1 million compared to $7.7 million in Q1 2020. The cash balance as of March 31, 2021, stood at $78 million, despite a $6.6 million decrease from the prior quarter.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the completion of enrollment in its 100-patient Motiva Mia® case series in Costa Rica, approved by the Institutional Review Board. The study began in December 2020, following a previous case series in Asia. Led by 15 board-certified plastic surgeons from various countries, this prospective study aims to assess a minimally invasive breast enhancement procedure. The company has also submitted tools for CE marking, marking significant progress in its global regulatory strategy.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is set to announce its financial results for Q1 2021 on May 5, 2021, before market opens. A conference call will follow at 8:30 am ET. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering innovative silicone gel-filled breast implants branded as Motiva Implants®. These implants are available in over 80 countries and produced in compliance with strict quality standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported record fourth quarter sales of $27.0 million, up 11% year-over-year, and provided 2021 guidance of $110 million to $112 million, reflecting a 30% to 32% growth. Operating expenses rose to $22.7 million, with a net loss from operations of $8.0 million. The company maintains a robust cash balance of $84.5 million. Key advancements include receiving CE mark for the new Motiva Ergonomix2 silicone implants and progress toward U.S. and Chinese market entry, with a total addressable market for Motiva Mia estimated at $4-5 billion.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Raj Denhoy as Head of Strategy and Investor Relations. Denhoy, formerly with Jefferies Group, brings over two decades of experience in the medical device industry. His role will involve defining corporate strategy and enhancing investor communication as the company aims for global leadership in breast aesthetics and reconstruction. Denhoy emphasized potential growth through the global rollout of Motiva implants and the upcoming MIA procedure, signaling optimism for sustained value creation.
Establishment Labs Holdings (NASDAQ: ESTA) is set to announce its financial results for Q4 2020 on March 10, 2021, before market open. A conference call will follow at 8:30 AM ET to discuss these results. The company specializes in women’s health, primarily in breast aesthetics, with its innovative Motiva Implants® and related technologies. Products are available in over 80 countries, adhering to strict regulatory standards. The company also initiated a clinical trial in the U.S. for Motiva Implants® after receiving FDA approval in March 2018.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós and CFO Renee Gaeta will attend the Cowen 41st Annual Healthcare Conference from March 1-4, 2021. They are scheduled to present on March 2, 2021, at 9:50 am ET. A live webcast of their presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women’s health, primarily in breast aesthetics and reconstruction, with products like Motiva Implants® available in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) hosted a virtual event on February 9, 2021, discussing its Motiva MIA system for minimally invasive breast augmentation. The MIA study shows reduced procedure time, lower post-operative pain, and quicker recovery compared to traditional methods. The company has expanded its clinical trials in Costa Rica and Thailand, aiming for regulatory approvals worldwide. Market research estimates a global market potential of $4-5 billion, indicating strong interest in the MIA system, with 50% of surveyed women willing to consider it over traditional surgery.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CEO Juan José Chacón-Quirós and CFO Renee Gaeta will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021. They are scheduled to present at 10:00 am ET on February 19. The conference offers a platform for discussions on the company's focus on women's health, particularly in breast aesthetics with their Motiva Implants®.
A live webcast and archived presentation will be accessible on their investor relations website.
Establishment Labs Holdings (NASDAQ: ESTA), a medical technology firm specializing in women’s health, announced a virtual investor event on Feb. 9, 2021, to discuss its innovative Motiva Mia® system. This system aims to provide a minimally invasive breast enhancement procedure with reduced recovery time and less pain compared to traditional methods. Renowned medical professionals will share insights from a recent clinical study involving 30 patients. Despite this advancement, the Motiva Mia system is not yet commercially approved. Registration for the event is available online.